The work group declined to create a new measure, and encourages providers to identify a measure to meet their population needs. We treat Parkinson's disease and Alzheimer dementia. Notably, two prospective clinical trials have shown safety and improved efficacy in adding low molecular weight heparins to pneumatic devices, , though the majority of patients still do not receive chemoprophylaxis after brain tumor surgery. It is anticipated that by measuring performance, a treatment gap will be confirmed and further opportunities for improvement will be identified. Basic science and clinical trials play a pivotal role in this subspecialty to improve outcomes for neuro-oncological disorders.
In the end, the group delineated five areas that were feasible for measure development, as they had support from scientific literature and evidence of gaps in care. Thus, a treatment gap does exist. The most frequently used chemotherapies in neuro-oncology are oral, including temozolomide, lomustine, and procarbazine, and errors in the home administration of oral chemotherapy are associated with a high likelihood of harm. Candidate measure concepts were extensively reviewed and edited prior to a work group vote to approve, reject, or abstain on each measure during teleconference meetings. Results The workflow of group measure proposal, evaluation, and development is shown in. This fund will allow us to continue to attract the most talented post-graduate trainees.
Canadian participants can claim credit for each interview by listening to the interview, completing the posttest and evaluation, and reporting the activity in. Canadian participants should visit to record learning and outcomes. The inclusion of an outcome measure in this set creates an opportunity for improvement even for high-volume neuro-oncology institutions that might otherwise achieve the named process measures nearly perfectly. However, perfection is not anticipated for any measure; instead, performance data should serve as an internal benchmark for provider, practice, and hospital quality improvement opportunities. Chemotherapy Education and Informed Consent American Society of Clinical Oncology and Oncology Nursing Society guidelines indicate that all patients who are prescribed chemotherapy should be provided education in advance of prescription. Hospice and Palliative Care — Treatment Preferences. Ultimately these measures were not developed for a variety of reasons, including difficulty capturing data due to current electronic medical records practices, lack of evidence, lack of a known gap in care practice, and development of similar measures by others in related fields.
Disclaimer: This article is published simultaneously in Neuro-Oncology and Neurology. Continuum Audio is an Accredited Self-Assessment Program Section 3 as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Office of Continuing Medical Education and Professional Development, University of Calgary, on June 1, 2018. Conclusion The goal of quality measures is to guide their users to evidence-based improvements in care and, eventually, health care outcomes. Our fellowship program offers one- to two-year training periods for candidates who have completed an adult or pediatric neurology residency and have attained the qualifications necessary to sit for the American Board of Psychiatry and Neurology examination. Sanders serves as a member of the National Quality Forum Palliative and End-of-Life Standing Committee. Supplementary Material Supplementary data are available at Neuro-Oncology online.
We also perform Botox injections and nerve blocks for severe headache management. A compliment to each journal article, Continuum Audio extends the content beyond the written word through lively conversations with the Continuum Audio editors about each article topic. Instead, providers, practices, and hospitals are encouraged to identify the one or two measures that would be most meaningful for their patient populations. The measure once finalized will be available at: From the time of the initial meeting to Board approvals, development of this measurement set took ten months July 2016 to April 2017. This data may highlight practice changes that providers can make to improve quality of patient care e. Fellowship Overview Neuro-Oncology is a growing subspecialty that is in constant evolution as novel diagnostic strategies, therapeutics, and prognostic factors are being discovered. Based on measurement set approval by two professional societies with a marked decrease in turnaround time, similar number of measures developed, and similar amount of public commentary, the work group determined the expedited, virtual measure development process to be an appropriate surrogate for previously published processes.
The work group created these measures with the primary intention of improving clinical practice, understanding that providers act with best intentions to do no harm. Credit cannot be claimed for issues prior to June 2018. Consultations and compassionate care for general neurology including headaches, migraine, stroke, memory problems, vertigo, neuropathy, concussions, seizures and epilepsy. Measures will be periodically evaluated every three years and updated as necessary to reflect continued utility in quality neuro-oncology care. Education and active consent obtained for same chemotherapy prescription in the past 12-month period. Efforts were made to publicize this opportunity both to patients and to caregivers in the interest of identifying meaningful measures.
Should performance rates near perfect compliance, the work group will evaluate the continued need for these measures during the next scheduled update. Multidisciplinary Care Plan Development Multidisciplinary tumor board discussions for care plan determination have been associated with improved quality and coordination of care in various cancers, and are a well-established quality indicator in oncology care, both domestically and internationally. Once the work group was constituted, members drafted candidate measures with attendant technical specifications, identified measures ripe for development via a modified Delphi process, and refined candidate measures via teleconference meetings. Our goal is to train future leaders in the field of academic neuro-oncology. Patients with tissue insufficient for molecular testing. The final work group comprised nine members representing multi-stakeholder interests for patients with neuro-oncology conditions. Opportunities for Improvement Following a thorough literature search, the work group identified five areas in need of quality improvement.
The process began with a literature review by a medical librarian, identifying 1,052 relevant abstracts, 25 potential guidelines or systematic reviews, and 60 articles providing supporting evidence. . Program accreditation expires May 31, 2021. Toward this end, several authors have published work on quality-based practice and on the inclusion of patient reported outcomes in brain tumor care. The hope is that these measures will help drive clinical practice improvement and better patient outcomes. There is no requirement that all measures be used by a provider or hospital. The first year of our fellowship focuses primarily on the clinical training.